Above-median levels of miR-126 in circulating microvesicles were associated with a reduced risk of major adverse cardiovascular events in patients with stable CAD (HR 0.485; 95% CI 0.278-0.846; P=0.007).
Cohort (n=181)
Do above-median levels of miR-126 and miR-199a in circulating microvesicles predict cardiovascular events in patients with stable coronary artery disease?
Microvesicle-contained miR-126 and miR-199a, but not freely circulating miRNAs, serve as prognostic biomarkers for predicting cardiovascular events in patients with stable coronary artery disease.
Hazard Ratio: 0.485 (95% CI 0.278–0.846)
p-value: p=0.007
BACKGROUND: Circulating microRNAs (miRNAs) are differentially regulated and selectively packaged in microvesicles (MVs). We evaluated whether circulating vascular and endothelial miRNAs in patients with stable coronary artery disease have prognostic value for the occurrence of cardiovascular (CV) events. METHODS AND RESULTS: Ten miRNAs involved in the regulation of vascular performance-miR-126, miR-222, miR-let7d, miR-21, miR-20a, miR-27a, miR-92a, miR-17, miR-130, and miR-199a-were quantified in plasma and circulating MVs by reverse transcription polymerase chain reaction in 181 patients with stable coronary artery disease. The median duration of follow-up for major adverse CV event-free survival was 6.1 years (range: 6.0-6.4 years). Events occurred in 55 patients (31.3%). There was no significant association between CV events and plasma level of the selected miRNAs. In contrast, increased expression of miR-126 and miR-199a in circulating MVs was significantly associated with a lower major adverse CV event rate. In univariate analysis, above-median levels of miR-126 in circulating MVs were predictors of major adverse CV event-free survival (hazard ratio: 0.485 95% CIAUTHOR: Is 95% CI correct?: 0.278 to 0.846; P=0.007) and percutaneous coronary interventions (hazard ratio: 0.458 95% CI: 0.222 to 0.945; P=0.03). Likewise, an increased level of miR-199a in circulating MVs was associated with a reduced risk of major adverse CV events (hazard ratio: 0.518 95% CI: 0.299 to 0.898; P=0.01) and revascularization (hazard ratio: 0.439 95% CI: 0.232 to 0.832; P=0.01) in univariate analysis. miRNA expression analysis in plasma compartments revealed that miR-126 and miR-199a are present mainly in circulating MVs. MV-sorting experiments showed that endothelial cells and platelets were found to be the major cell sources of MVs containing miR-126 and miR-199a, respectively. CONCLUSION: MVs containing miR-126 and miR-199a but not freely circulating miRNA expression predict the occurrence of CV events in patients with stable coronary artery disease.
Jansen et al. (Tue,) conducted a cohort in stable coronary artery disease (n=181). Above-median levels of miR-126 in circulating microvesicles vs. Below-median levels was evaluated on major adverse CV event-free survival (HR 0.485, 95% CI 0.278 to 0.846, p=0.007). Above-median levels of miR-126 in circulating microvesicles were associated with a reduced risk of major adverse cardiovascular events in patients with stable CAD (HR 0.485; 95% CI 0.278-0.846; P=0.007).